Artiva Biotherapeutics Files Definitive Proxy Statement
Ticker: ARTV · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1817241
| Field | Detail |
|---|---|
| Company | Artiva Biotherapeutics, Inc. (ARTV) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
Related Tickers: ARVA
TL;DR
Artiva Bio (ARVA) filed its proxy statement for the annual meeting. Shareholders vote on key company matters.
AI Summary
Artiva Biotherapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its fiscal year ending December 31, 2024. The filing pertains to the company's annual meeting and related shareholder matters. The company is based in San Diego, California, and operates in the biological products sector.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda for the annual meeting, details executive compensation, and provides information on director nominations, enabling informed voting decisions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently introduce new financial risks.
Key Numbers
- 2024 — Fiscal Year End (The proxy statement covers the company's performance and governance for this period.)
Key Players & Entities
- Artiva Biotherapeutics, Inc. (company) — Registrant
- 0001193125-25-101364 (filing_id) — Accession Number
- 20250429 (date) — Filing Date
- 20250624 (date) — Period of Report
- San Diego, CA (location) — Company Headquarters
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is a document filed with the SEC by a company that is soliciting shareholder votes for its annual meeting or other corporate actions. It provides detailed information about the matters to be voted on, including director nominations, executive compensation, and other corporate governance issues.
When was this specific DEF 14A filing made by Artiva Biotherapeutics, Inc.?
Artiva Biotherapeutics, Inc. filed this Definitive Proxy Statement on April 29, 2025.
What is the fiscal year end for Artiva Biotherapeutics, Inc. as indicated in the filing?
The fiscal year end for Artiva Biotherapeutics, Inc. is December 31.
Where is Artiva Biotherapeutics, Inc. located?
Artiva Biotherapeutics, Inc. is located at 5505 Morehouse Drive, San Diego, CA 92121.
What is the SIC code for Artiva Biotherapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Artiva Biotherapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Artiva Biotherapeutics, Inc. (ARTV).